The AHEAD 3-45 Study is looking at how well the drug lecanemab works and how safe it is for people who might be at the very early stages of Alzheimer's disease. Alzheimer's disease is a brain disorder that affects memory and thinking. In this study, researchers want to see if lecanemab can help keep the brain healthy and slow down changes seen in Alzheimer's. The study will last for about 216 weeks, which is a little over four years, and includes multiple tests and check-ups.
Key Points:
- Duration: The study lasts for about 4 years, with regular check-ups.
- Eligibility: Participants should be between ages 55-80 and meet certain health criteria.
- Safety: The study will evaluate the long-term safety of the treatment.
Participants will need to have a study partner who can help provide information about their daily activities. They should not have certain health issues like recent strokes, or certain metal implants that can interfere with MRI scans. If you meet the criteria and are interested, this study could help advance understanding and treatment of early Alzheimer's disease.